Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.

"I think MRI has really been perhaps the most transformative development in the realm of prostate cancer screening since I came into the field," says Stacy Loeb, MD, MSc, PhD (Hon. The agency is ...

Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today. "I think MRI has really been perhaps the most transformative development in the realm of ...

Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...

A panel of experts discusses the evolution of BPH treatment, as well as how their practices have been affected by COVID-19.

TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...

Niraparib addition to abiraterone and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially those with BRCA mutations. The trial emphasized the importance of genomic testing ...

Bladder Cancer | Clinical | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

The updated guideline emphasizes a patient-centered, risk-based approach, prioritizing symptom resolution and antimicrobial stewardship over microbial eradication. New recommendations include ...

In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has ...